Korro Bio, INC 10-Q quarterly reports

Korro Bio, Inc. (KRRO) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing operating losses and strategic adjustments, including workforce reductions and the termination of a clinical trial.

Korro Bio, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $19.6 million and a cash runway extending into the second half of 2028 following a significant private placement.

Korro Bio reported a widened net loss in Q3 2025, announced a pivot for its AATD program after KRRO-110 failed to meet protein targets, and paused its collaboration with Novo Nordisk.

Korro Bio, a clinical-stage biopharmaceutical company, reported increased net losses and cash burn for the first half of 2025, despite initiating collaboration revenue and advancing its lead RNA editing program, KRRO-110, into Phase 1/2a clinical trials.

Korro Bio, a clinical-stage biopharmaceutical company, announced its first quarter 2025 financial results, highlighting progress in its AATD clinical program and strategic streamlining efforts.

Korro Bio, a biopharmaceutical company focused on RNA editing, reported its third quarter 2024 financial results, highlighting a collaboration with Novo Nordisk and progress in its clinical programs.

Korro Bio, a biopharmaceutical company focused on RNA editing, reported a net loss of $41.4 million for the first six months of 2024, while highlighting progress in its preclinical programs and financial runway.

Korro Bio, a biopharmaceutical company focused on RNA editing, released its first quarter 2024 financial results, highlighting ongoing research and development efforts and a recent $70 million private placement.